BRIEF-Nference And Beigene Collaborate To Drive New B-Cell Cancer Research

Nference and Beigene Collaborate to Drive New B-Cell Cancer Research

BUZZ-BeiGene slides after halting lung cancer drug trial due to futility

BRIEF-Beigene Provides Update On The Ociperlimab (Bgb-A1217) Clinical Development Program

Beigene Provides Update on the Ociperlimab (Bgb-a1217) Clinical Development Program

Beigene Ltd - Study Unlikely to Meet Primary Endpoint of Overall Survival

Beigene Ltd - Independent Data Monitoring Committee Recommends Termination of Phase 3 Advantig-302 Trial

Beigene Ltd - to Discontinue Clinical Development of Ociperlimab for Lung Cancer

BRIEF-Beigene Receives Positive CHMP Opinion For TEVIMBRA As A First-Line Treatment For Extensive-Stage Small Cell Lung Cancer

Beigene Receives Positive Chmp Opinion for Tevimbra® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

BeiGene Net Loss Narrows 27% in 2024

BRIEF-Beigene Posts Total Revenues For Year US$3.8 Billion

Beigene - Total Revenues for Year US$1.4 Bln

Beigene Ltd - Net Loss for Year US$644.8 Million

BeiGene Shareholder Hillhouse Pares Stake in Cancer Drug Company

BeiGene Commences New Offering Period for Employee Share Purchase Plan

BRIEF-Tevimbra Approved In U.S.

Tevimbra Approved in U.S. for First-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination With Chemotherapy

Beigene Ltd : Bofa Global Research Raises to Buy From Neutral; Raises Price Objective to $320 From $207

BeiGene's Q4'24 Loss Narrows